{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T18:08:14Z","timestamp":1789668494823,"version":"4.0.1"},"reference-count":25,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Annals of Neurosciences"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Intravenous thrombolysis with alteplase has been the standard for acute ischaemic stroke (AIS) within 4.5 h, but tenecteplase (TNK) is gaining promising corner in intravenous thrombolysis with some unique features and superior efficacy in large vessel occlusion (LVO).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study evaluates real-world TNK outcomes at a Central Indian tertiary centre.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This ambispective single-centre study included 36 AIS patients presenting within &lt;4.5 h of onset, meeting inclusion criteria (age &gt;18 years, National Institutes of Health Stroke Scale (NIHSS)-assessed, blood pressure &lt;185\/110 mmHg, no contraindications). Weight-based TNK (0.25 mg\/kg bolus) was administered. NIHSS was noted at admission, 48 h, 7 days and discharge; modified Rankin Scale at discharge and at 90 days was also recorded. Demographics, comorbidities, vessel angiography status and complications were analysed using descriptive statistics and\n                      <jats:italic toggle=\"yes\">t<\/jats:italic>\n                      -tests (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; .05 significant).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The mean age was 57.67 \u00b1 14.32 years, and 75% of patients were males. Hypertension (61.1%) and smoking (30.6%) were the predominant comorbidities. Mild stroke (NIHSS 1\u20135) occurred in 58.33% of cases, and LVOs were present in 27.78% (bilateral internal carotid artery (ICA) in 13.89%, middle cerebral artery M1\/M2 in 13.89%). Patients with bilateral ICA occlusions experienced a mean NIHSS reduction of 6 points, compared to 3.5 points in others (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = .0188). Successful thrombolysis with TNK was achieved in 77.78% of cases. Complications included haemorrhagic transformation in 8.33% and mortality in 8.33% (unrelated to TNK). Age and comorbidities did not predict outcomes (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &gt; .05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>TNK use had robust success in lowering NIHSS scores, particularly in LVOs, with excellent safety, being a single bolus, more cost-effective, no time wastage for infusion preparation supporting its preference over standard alteplase. TNK may be a better choice in resource-limited set-up. Multicentre trials are needed for its widespread adoption and also for its conjunctive use with mechanical thrombectomy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/09727531261479824","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:38:57Z","timestamp":1789468737000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Experience with Tenecteplase in Treatment of Acute Ischaemic Stroke in Window: Analysis and Outcomes at a Tertiary Care Institute in Central India"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7724-5247","authenticated-orcid":false,"given":"Priyanka V.","family":"Kashyap","sequence":"first","affiliation":[{"name":"Department of Neurology, All India Institute of Medical Sciences Bhopal, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaibhav O.P.","family":"Pandey","sequence":"additional","affiliation":[{"name":"Department of Neurology, All India Institute of Medical Sciences Bhopal, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.308413"},{"issue":"10","key":"e_1_3_7_3_2","first-page":"795","article-title":"Global, regional, and national burden of stroke, 1990\u20132019: a systematic analysis","volume":"20","author":"GBD 2019 Stroke Collaborators","year":"2021","unstructured":"GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke, 1990\u20132019: a systematic analysis. Lancet Neurol. 2021; 20(10): 795\u2013820.","journal-title":"Lancet Neurol"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512143332401"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109842"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716405"},{"issue":"6","key":"e_1_3_7_7_2","first-page":"e777","article-title":"Tenecteplase vs. alteplase for acute ischemic stroke: a systematic review and meta-analysis","volume":"96","author":"Katsanos AH","year":"2021","unstructured":"Katsanos AH, , Safouris A, , Sarraj A, . Tenecteplase vs. alteplase for acute ischemic stroke: a systematic review and meta-analysis. Neurology. 2021; 96(6): e777\u2013e788.","journal-title":"Neurology"},{"issue":"12","key":"e_1_3_7_8_2","first-page":"e344","article-title":"Guidelines for the early management of patients with acute ischemic stroke: 2019 update","volume":"50","author":"Powers WJ","year":"2019","unstructured":"Powers WJ, , Rabinstein AA, , Ackerson T, . Guidelines for the early management of patients with acute ischemic stroke: 2019 update. Stroke. 2019; 50(12): e344\u2013e418.","journal-title":"Stroke"},{"key":"e_1_3_7_9_2","article-title":"Bolus-infusion delays of alteplase during thrombolysis in acute ischaemic stroke and functional outcome at 3 months","volume":"2014","author":"Acheampong P","year":"2014","unstructured":"Acheampong P, , May MT, , Ford GA, . Bolus-infusion delays of alteplase during thrombolysis in acute ischaemic stroke and functional outcome at 3 months. Stroke Res Treat. 2014; 2014: 358640. DOI: 10.1155\/2014\/358640","journal-title":"Stroke Res Treat"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000086"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60834-3"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.1586\/erc.10.56"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.8.1015"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c6046"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60584-5"},{"key":"e_1_3_7_16_2","unstructured":"Menon BK Mitha AP Hill MD . Safety and efficacy of tenecteplase versus alteplase in stroke patients with carotid tandem lesions: an AcT trial analysis. Front Neurol. 2023; 14: 10903116. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10903116\/"},{"key":"e_1_3_7_17_2","unstructured":"Huang X Xu L Tan S . Safety and efficacy of tenecteplase versus alteplase in tandem carotid occlusions: a meta-analysis and pooled analysis of ETIS and TETRIS studies. Stroke Vasc Neurol. 2024 Oct 16. https:\/\/svn.bmj.com\/content\/early\/2024\/10\/17\/svn-2024-003318"},{"key":"e_1_3_7_18_2","unstructured":"Raju A Khera PS Palla M . Tenecteplase for acute ischemic stroke after heparin reversal: a case report. Front Stroke. 2024; 4: 1375473. https:\/\/www.frontiersin.org\/journals\/stroke\/articles\/10.3389\/fstro.2024.1375473\/full"},{"key":"e_1_3_7_19_2","unstructured":"Deng Y Qiang L Feng J . A pooled analysis of ETIS and TETRIS: tenecteplase for large vessel occlusion and tandem lesion stroke. Front Neurol. 2023; 14: 10916828. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10916828\/"},{"key":"e_1_3_7_20_2","unstructured":"Sharma D Soto-Gutierrez A Elkind MSV . Efficacy of tenecteplase in large vessel occlusion stroke: results from recent publications. Stroke. 2025; 56: e234\u2013e239. https:\/\/www.ahajournals.org\/doi\/10.1161\/STROKEAHA.125.052511"},{"key":"e_1_3_7_21_2","doi-asserted-by":"crossref","unstructured":"Gong F Liu Z Zhuang Y . Comprehensive review of tenecteplase for thrombolysis in acute ischemic stroke. J Am Heart Assoc. 2024; 13: e031692. https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.123.031692","DOI":"10.1161\/JAHA.123.031692"},{"key":"e_1_3_7_22_2","unstructured":"Tang X Pang X Wang H . Tenecteplase versus alteplase in medium vessel occlusions: a multicenter randomized controlled trial. J Stroke. 2024; 26: 317\u2013327. https:\/\/www.j-stroke.org\/journal\/view.php?doi=10.5853%2Fjos.2023.03713"},{"key":"e_1_3_7_23_2","unstructured":"Patel S Thomas M Rossi C . Intravenous tenecteplase thrombolysis and endovascular therapy in acute stroke: case series and review. Front Neurol. 2025; 15: 12376366. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12376366\/"},{"key":"e_1_3_7_24_2","article-title":"2026 Guideline for the early management of patients with acute ischemic stroke: a guideline from the American Heart Association\/American Stroke Association","author":"Prabhakaran S","unstructured":"Prabhakaran S, , Gonzalez NR, , Zachrison KS, . 2026 Guideline for the early management of patients with acute ischemic stroke: a guideline from the American Heart Association\/American Stroke Association. Stroke. DOI: 10.1161\/STR.0000000000000513","journal-title":"Stroke"},{"key":"e_1_3_7_25_2","doi-asserted-by":"publisher","DOI":"10.5853\/jos.2018.01998"},{"key":"e_1_3_7_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1415061"}],"container-title":["Annals of Neurosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09727531261479824","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09727531261479824","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09727531261479824","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:48:42Z","timestamp":1789667322000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09727531261479824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":25,"alternative-id":["10.1177\/09727531261479824"],"URL":"https:\/\/doi.org\/10.1177\/09727531261479824","relation":{},"ISSN":["0972-7531","0976-3260"],"issn-type":[{"value":"0972-7531","type":"print"},{"value":"0976-3260","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"article-number":"09727531261479824"}}